Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial

Eur Urol Focus. 2019 Sep;5(5):849-852. doi: 10.1016/j.euf.2018.02.005. Epub 2018 Feb 21.

Abstract

The MAGNOLIA study, investigating the concept of perioperative immunotherapy in muscle- invasive bladder cancer, was prematurely terminated. The lessons learned that should be considered before initiating and conducting future clinical trials in this field are highlighted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm / therapeutic use*
  • Chemotherapy, Adjuvant
  • Clinical Trials, Phase II as Topic
  • Cystectomy
  • Double-Blind Method
  • Early Termination of Clinical Trials
  • Humans
  • Immunotherapy*
  • Neoplasm Invasiveness
  • Neoplasm Proteins / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins / therapeutic use
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / surgery

Substances

  • Antigens, Neoplasm
  • MAGEA3 protein, human
  • Neoplasm Proteins
  • Recombinant Proteins